NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

HBM Healthcare Investments

Press release

Zug, 3 September 2012

HBM Healthcare Investments starts new share buy-back programme

The share buy-back programme which began in September 2009 was brought to a close on 31 August 2012. A total of 1,610,000 registered shares, corresponding to 15% of 10.7 million shares issued at the time, for a total amount of CHF 71.9 million were repurchased via a separate trading line on SIX Swiss Exchange for the purpose of cancellation as part of a capital reduction.

The Ordinary Shareholders' Meeting of HBM Healthcare Investments Ltd on 22 June 2012 approved a new share buy-back programme for a maximum of 920,000 registered shares. This represents 10% of the shares entered in the share register at the end of the current capital reduction process. The shares will also be cancelled as part of a further reduction in capital. The buy-back programme will once again be conducted via a separate trading line on SIX Swiss Exchange. It will begin on 10 September 2012 and will be completed no later than 30 June 2015.

The actual scope of the buy-back programme will depend on business performance, available liquidity, and the market environment. UBS Inc has been engaged to conduct the programme.

For further information, please contact Dr. Andreas Wicki, tel.: +41 41 768 11 08, andreas.wicki@hbmhealthcare.com

Information on HBM Healthcare Investments Ltd

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of some 25 promising companies in the biotechnology/human medicine, medical technology and diagnostics sectors. Many of these companies have their lead products already available on the market, or at an advanced stage of development. The focus of investment is on follow-on financing for existing portfolio companies. These portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotech companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

HBM Healthcare Investments

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

www.hbmhealthcare.com